SMC accepts MSD's KEYTRUDA®▼ (pembrolizumab) as monotherapy

MSD’s pembrolizumab approved by Scottish Medicines Consortium

The Scottish Medicines Consortium (SMC) has accepted MSD's KEYTRUDA®▼ (pembrolizumab) as monotherapy for the adjuvant treatment of adults with stage III melanoma with lymph...
Roche test aids clinicians in accelerating tuberculosis diagnosis and treatment

Roche test detects antimicrobial resistance within TB

Roche has announced the CE-IVD launch of the cobas® MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. This assay is part of the...
Army of NHS experts brought in to care homes to tackle over-medication

NHS experts band together to tackle ‘chemical cosh’ in care homes

An 'army' of health experts has been recruited by NHS England to help prevent care home residents being given too many medicines as charities...
State of the Discovery Nation published by MDC and BIA

State of the Discovery Nation report shares insights into UK medicines discovery industry

Medicines Discovery Catapult and the BioIndustry Association (BIA) have unveiled their 2019 State of the Discovery Nation report, providing new insights into the UK’s...
Phase 3 CheckMate -498 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo

Bristol-Myers Squibb trial fails to meet primary endpoint

Bristol-Myers Squibb's Phase 3 CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated...
Data from Symbicort Turbuhaler Novel START trial among 73 AstraZeneca abstracts accepted for presentation at ATS

Sanofi’s Dupixent® ▼ (dupilumab) licensed in EU

Sanofi has announced that Dupixent® ▼ (dupilumab) has been licensed in the EU for the treatment of severe asthma with type 2 inflammation. The European...

Obesity an increasing factor in hospital admissions

Admissions to NHS hospitals, where obesity was recorded as either a primary or secondary diagnosis, increased by 15% (94,000) in 2017/18 compared to 2016/17. The...
AstraZeneca and Daiichi Sankyo announce positive top-line results for pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan

Pivotal Phase II DESTINY-Breast01 trial meets primary endpoint

AstraZeneca and Daiichi Sankyo have announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate...
competition to create Digital Innovation Hubs

MRC to run competition process for Digital Innovation Hubs

The MRC is to run a competition process on behalf of Health Data Research UK, to create Digital Innovation Hubs: centres of excellence dedicated...
State of the Discovery Nation published by MDC and BIA

Novartis announces results of MS Progression Discussion Tool

Novartis has announced results from a validation study of the algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support...

Latest articles

Dr Harry Destecroix of Ziylo wins 2019 Pharmaceutical Industry Network Group Innovation Award

Biotech leader wins PING Innovation Award 2019

Dr Harry Destecroix of Ziylo has won the 2019 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by pharma and life sciences specialist law...
NICE recommend funding for Spinraza

NICE recommend funding for Spinraza for spinal muscular atrophy

The National Institute for Health and Care Excellence (NICE) has recommended funding for Spinraza (nusinersen) on the National Health Service (NHS). The positive recommendation, subject to...
Data from Symbicort Turbuhaler Novel START trial among 73 AstraZeneca abstracts accepted for presentation at ATS

New data from Novel START trial accepted for presentation

New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American...

Popular articles

pain relief patch released by nurofen

Nurofen launches a 24 hour ibuprofen pain relief patch

Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen.  Despite body pain being among the most commonly...
new migraine data for Aimovig presented by Novartis

Novartis presents new migraine data for Aimovig®▼ (erenumab)

Novartis presents new migraine data for Aimovig®▼ (erenumab) demonstrating sustained efficacy to 52 weeks. Novartis has announced that new data from two follow-up studies of...
Data from Symbicort Turbuhaler Novel START trial among 73 AstraZeneca abstracts accepted for presentation at ATS

New data from Novel START trial accepted for presentation

New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American...

Top 5 R&D hubs in the UK

Read this cover story in the June issue of Pf Magazine here.    Join us on a tour of inspirational research and development centres. ...
Dr Harry Destecroix of Ziylo wins 2019 Pharmaceutical Industry Network Group Innovation Award

Biotech leader wins PING Innovation Award 2019

Dr Harry Destecroix of Ziylo has won the 2019 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by pharma and life sciences specialist law...